That is why it has sometimes been prescribed by providers across the US off-label for obesity treatment, based on their judgement
Barriers to initiating treatment may include delayed recognition of obesity as a disease by public health and medical organizations, provider biases regarding patients with obesity, lack of reimbursement leading to out-of-pocket costs to patients, inadequate training of providers, historical safety issues with AOMs, and perceptions of patients and their caregivers regarding the efficacy of AOMs [14,15,16,17]
Another crucial factor is the usage rate
Food and Drug Administration, unlike the popular medications themselves
It is gradual, not instant
They should also ask which pharmacy may fill prescriptions